JP2012031209A5 - - Google Patents

Download PDF

Info

Publication number
JP2012031209A5
JP2012031209A5 JP2011244443A JP2011244443A JP2012031209A5 JP 2012031209 A5 JP2012031209 A5 JP 2012031209A5 JP 2011244443 A JP2011244443 A JP 2011244443A JP 2011244443 A JP2011244443 A JP 2011244443A JP 2012031209 A5 JP2012031209 A5 JP 2012031209A5
Authority
JP
Japan
Prior art keywords
dry powder
powder formulation
glycopyrrolate
formulation according
magnesium stearate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011244443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012031209A (ja
JP5124718B2 (ja
Filing date
Publication date
Priority claimed from GBGB0409703.6A external-priority patent/GB0409703D0/en
Application filed filed Critical
Publication of JP2012031209A publication Critical patent/JP2012031209A/ja
Publication of JP2012031209A5 publication Critical patent/JP2012031209A5/ja
Application granted granted Critical
Publication of JP5124718B2 publication Critical patent/JP5124718B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011244443A 2004-04-30 2011-11-08 医薬組成物 Expired - Lifetime JP5124718B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
GB0409703.6 2004-04-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007510045A Division JP5000483B2 (ja) 2004-04-30 2005-04-29 医薬組成物

Publications (3)

Publication Number Publication Date
JP2012031209A JP2012031209A (ja) 2012-02-16
JP2012031209A5 true JP2012031209A5 (enExample) 2012-07-05
JP5124718B2 JP5124718B2 (ja) 2013-01-23

Family

ID=32408337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007510045A Expired - Lifetime JP5000483B2 (ja) 2004-04-30 2005-04-29 医薬組成物
JP2011244443A Expired - Lifetime JP5124718B2 (ja) 2004-04-30 2011-11-08 医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007510045A Expired - Lifetime JP5000483B2 (ja) 2004-04-30 2005-04-29 医薬組成物

Country Status (26)

Country Link
US (1) US20080063719A1 (enExample)
EP (3) EP1755555B1 (enExample)
JP (2) JP5000483B2 (enExample)
KR (1) KR101287919B1 (enExample)
CN (3) CN107252423A (enExample)
AU (2) AU2005237266B2 (enExample)
BR (1) BRPI0510500B8 (enExample)
CA (1) CA2563760C (enExample)
CY (6) CY1113069T1 (enExample)
DK (2) DK2422766T3 (enExample)
ES (2) ES2388289T3 (enExample)
GB (1) GB0409703D0 (enExample)
HU (4) HUE025463T2 (enExample)
IL (2) IL178651A (enExample)
LT (1) LTC2422766I2 (enExample)
LU (2) LU92176I2 (enExample)
MX (2) MXPA06012493A (enExample)
NO (1) NO20065502L (enExample)
NZ (1) NZ550479A (enExample)
PL (2) PL1755555T3 (enExample)
PT (2) PT1755555E (enExample)
RU (1) RU2396943C2 (enExample)
SG (3) SG186673A1 (enExample)
SI (2) SI1755555T1 (enExample)
WO (1) WO2005105043A2 (enExample)
ZA (1) ZA200609350B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US20100247658A1 (en) * 2007-12-13 2010-09-30 Gerhard Muhrer Organic compounds
WO2009074666A1 (en) * 2007-12-13 2009-06-18 Novartis Ag Organic compounds
US20090215734A1 (en) * 2008-02-26 2009-08-27 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
MX2011011123A (es) * 2009-04-24 2011-11-04 Schering Corp Formulaciones de aglomerado utiles en inhaladores de polvo seco.
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
EP2552414A4 (en) * 2010-03-31 2014-05-14 Glenmark Pharmaceuticals Ltd PHARMACEUTICAL POWDER COMPOSITION FOR INHALATION
WO2011120779A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
RU2580312C2 (ru) * 2010-04-21 2016-04-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ получения частиц с пониженным электростатическим зарядом
US20130157991A1 (en) 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
ES2705494T3 (es) 2010-08-31 2019-03-25 Glaxosmithkline Ip Dev Ltd Productos farmacológicos para la inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
NZ710740A (en) 2013-02-28 2020-06-26 Dermira Inc Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6454323B2 (ja) † 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
HRP20260435T1 (hr) * 2014-09-09 2026-05-08 Vectura Limited Formulacija koja sadrži glikopirolat, postupak i uređaj
BR112017007587A2 (pt) * 2014-10-16 2018-01-30 Teva Branded Pharmaceutical Products R&D Inc processo para preparar uma formulação farmacêutica em pó seca e inalável
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10617674B2 (en) 2016-03-08 2020-04-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
WO2017153702A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
ES2805434T3 (es) 2016-07-29 2021-02-12 Inke Sa Procedimiento de estabilización de tamaño de partícula
JP6781829B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
EP3595631B1 (en) * 2017-03-15 2024-11-27 Vectura Limited Method and formulation
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
KR102899004B1 (ko) 2017-12-11 2025-12-12 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
KR102696616B1 (ko) 2018-12-21 2024-08-20 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
US20250050042A1 (en) 2021-12-21 2025-02-13 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ES2292598T3 (es) 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
EP2283817B1 (en) * 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
NZ526059A (en) * 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
CN100496608C (zh) * 2001-03-30 2009-06-10 洁垢技术有限公司 药用气溶胶制剂
EP1501479A1 (en) * 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
WO2006100453A1 (en) * 2005-03-24 2006-09-28 Sosei R & D Ltd. Glycopyrronium salts and their therapeutic use

Similar Documents

Publication Publication Date Title
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2014523445A5 (enExample)
JP2007535522A5 (enExample)
JP2014005302A5 (enExample)
JP2017525712A5 (enExample)
JOP20120023B1 (ar) صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CA2796934A1 (en) Process for providing particles with reduced electrostatic charges
RU2012142295A (ru) Способ приготовления частиц носителя для сухих порошков для ингаляции
JP2010540547A5 (enExample)
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
JP2015500331A5 (enExample)
GEAP201814032A (en) Dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic for administration by inhalation
TR201000681A2 (tr) İnhalasyon yoluyla alınan kuru toz formülasyonları.
JP2015131825A5 (enExample)
JP2014218522A5 (enExample)
MY186229A (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
JP2014503593A5 (enExample)
JP2015510916A5 (enExample)
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
JP2017514858A5 (enExample)
FI3689332T3 (fi) Glykopyrrolaattia käsittävä formulaatio, menetelmä ja laitteisto
JP2015508411A5 (enExample)
CA2898043A1 (en) Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone